Kirin Pharma To Close Three Of Four R&D Sites In Japan
This article was originally published in PharmAsia News
Executive Summary
Kirin Pharma of Japan says it will close all but one of its R&D sites within the next three years. The firm, a subsidiary of Kirin Holdings, has four such sites in the Gunma Prefecture employing about 200 researchers. The company said the workers would be reassigned as it sells the closing facilities. Kirin R&D work is to be done in conjunction with another subsidiary, Kyowa Hakko Kogyo, after a merger scheduled for October. (Click here for more - a subscription may be required
You may also be interested in...
Outlicensing Offers Benefits to Japanese Pharma – Aveo CEO
By outlicensing early-stage compounds, Japanese pharma can gain benefits beyond receiving licensing fees, including de-risking Japanese development, according to a U.S. biotech CEO
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.